Rocket Pharmaceuticals Inc (RCKT)

$3.64 +0.05 (1.39%)
Market Cap 391.75M
Revenue (ttm) 0.00
Net Income (ttm) -223.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,996,900
Avg Vol 3,476,490
Day's Range N/A - N/A
Shares Out 109.12M
Stochastic %K 40%
Beta 0.52
Analysts Sell
Price Target $9.29

Company Profile

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogeni...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 659 8001
Address:
9 Cedarbrook Drive, Cranbury, United States
darntootin
darntootin May. 13 at 12:14 PM
$RCKT In the wider AAV gene therapy landscape, most approved or late-stage therapies act as "stabilizers" that slow down the decline of a degenerative disease. The Industry Benchmark: For example, Sarepta’s Elevidys (for Duchenne muscular dystrophy) or Novartis's Zolgensma (for Spinal Muscular Atrophy) are designed to halt or delay severe muscle wasting. They rarely restore lost function or drastically reduce structural damage that has already occurred. The RP-A501 Difference: Rocket's data goes beyond stabilization. Achieving a 24% reduction in left ventricular mass and completely reversing heart failure symptoms from NYHA Class II to Class I (asymptomatic) is viewed as an extraordinary breakthrough. It marks one of the few instances in gene therapy where a structural organ defect (cardiac hypertrophy) has been actively reversed humans
0 · Reply
Resilience1239
Resilience1239 May. 12 at 11:16 PM
$RCKT It took 3 years of holding and watching $AUPH go up and down, for one day to come home from work and you see its at $28. "Investing" is conviction and strength, strength to hold and strength to sell, vice versa. $RCKT will also get its run to the $30's. Just time and patience. 3220 shares strong and not selling, if you don't believe what's the point of the investment...
0 · Reply
xXCronoSXx
xXCronoSXx May. 12 at 1:51 PM
$RCKT pt? December? Next catalist?
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 12 at 1:26 PM
$RCKT RSI: 47.41, MACD: -0.0713 Vol: 0.16, MA20: 3.66, MA50: 4.03 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
darntootin
darntootin May. 11 at 9:53 PM
$RCKT I can wait not giving my shares to stuck shorts 🩳 for cheap
0 · Reply
Bellz22
Bellz22 May. 11 at 7:05 PM
$RCKT
0 · Reply
ctolliver1
ctolliver1 May. 11 at 3:10 PM
$RCKT why do they not close the ATM with the new funding available. Wouldn't that reassure investors?
4 · Reply
Shunbab
Shunbab May. 11 at 8:42 AM
$RCKT up over 4% premarket.... something afoot? 🤔
2 · Reply
BinaryLogic
BinaryLogic May. 9 at 11:02 AM
$MIST $RCKT $ABCL $OBIO $IMRX [Again] Investors are heavy in semi-conductors, AI/HPC and O&G related stocks presently which has created opportunities in-particular in biotechnology, small and large cap alike (IMO). That is not to suggest that major reversals here are imminent, but the setups are becoming increasingly opportunistic (IMO) intermediate term. UNCY COCH JSPR SCNX RANI TRAW NVAX MDT BSX
0 · Reply
drumma56
drumma56 May. 8 at 6:43 PM
$RCKT This is one F'd up ticker.
1 · Reply
Latest News on RCKT
Rocket Pharmaceuticals reports Q1 EPS (42c) , consensus (45c)

2026-05-07T21:49:50.000Z - 5 days ago

Rocket Pharmaceuticals reports Q1 EPS (42c) , consensus (45c)

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

May 7, 2026, 4:00 PM EDT - 5 days ago

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals announces $180M sale of priority review voucher

2026-04-28T11:29:11.000Z - 15 days ago

Rocket Pharmaceuticals announces $180M sale of priority review voucher

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

Apr 28, 2026, 7:00 AM EDT - 15 days ago

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

Rocket Pharmaceuticals price target raised to $9 from $8 at BofA

2026-03-30T10:30:11.000Z - 6 weeks ago

Rocket Pharmaceuticals price target raised to $9 from $8 at BofA

Rocket Pharmaceuticals price target raised to $11 from $9 at Leerink

2026-03-27T19:15:17.000Z - 6 weeks ago

Rocket Pharmaceuticals price target raised to $11 from $9 at Leerink

PRV reception could net Rocket $100M-$200M, says LifeSci Capital

2026-03-27T16:13:26.000Z - 6 weeks ago

PRV reception could net Rocket $100M-$200M, says LifeSci Capital

Rocket Pharmaceuticals stock weakness unwarranted, says Wedbush

2026-03-27T16:10:33.000Z - 6 weeks ago

Rocket Pharmaceuticals stock weakness unwarranted, says Wedbush

Rocket Pharmaceuticals Transcript: FDA announcement

Mar 27, 2026, 8:30 AM EDT - 6 weeks ago

Rocket Pharmaceuticals Transcript: FDA announcement

Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorder

Mar 27, 2026, 7:27 AM EDT - 6 weeks ago

Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorder

Rocket Pharmaceuticals announces FDA approval of Kresladi

2026-03-27T11:05:10.000Z - 6 weeks ago

Rocket Pharmaceuticals announces FDA approval of Kresladi

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Mar 27, 2026, 7:00 AM EDT - 6 weeks ago

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

FDA approves Rocket Pharmaceuticals’ Kresladi in LAD-I

2026-03-27T00:55:09.000Z - 6 weeks ago

FDA approves Rocket Pharmaceuticals’ Kresladi in LAD-I

Rocket Pharmaceuticals offers to sell up to $100M in common stock

2026-03-10T21:40:14.000Z - 2 months ago

Rocket Pharmaceuticals offers to sell up to $100M in common stock

Rocket Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 9:20 AM EDT - 2 months ago

Rocket Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Rocket Pharmaceuticals files $400M mixed securities shelf

2026-03-02T21:21:06.000Z - 2 months ago

Rocket Pharmaceuticals files $400M mixed securities shelf

Rocket Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 11:10 AM EST - 2 months ago

Rocket Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Rocket Pharmaceuticals price target raised to $3 from $2 at Goldman Sachs

2026-03-02T11:54:20.000Z - 2 months ago

Rocket Pharmaceuticals price target raised to $3 from $2 at Goldman Sachs

Rocket Pharmaceuticals price target raised to $10 from $8 at Cantor Fitzgerald

2026-02-27T15:05:34.000Z - 2 months ago

Rocket Pharmaceuticals price target raised to $10 from $8 at Cantor Fitzgerald

Rocket Pharmaceuticals reports Q4 EPS (38c), consensus (42c)

2026-02-26T21:17:28.000Z - 2 months ago

Rocket Pharmaceuticals reports Q4 EPS (38c), consensus (42c)

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

Feb 26, 2026, 4:00 PM EST - 2 months ago

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Feb 23, 2026, 7:00 AM EST - 2 months ago

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Rocket Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 2:15 PM EST - 4 months ago

Rocket Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Rocket Pharmaceuticals price target lowered to $5 from $7 at Morgan Stanley

2026-01-08T12:46:26.000Z - 4 months ago

Rocket Pharmaceuticals price target lowered to $5 from $7 at Morgan Stanley

Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM EST - 4 months ago

Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Rocket Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 7:55 AM EST - 5 months ago

Rocket Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 7:00 AM EST - 6 months ago

Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

Rocket Pharmaceuticals price target lowered to $8 from $10 at BofA

2025-11-18T14:42:08.000Z - 6 months ago

Rocket Pharmaceuticals price target lowered to $8 from $10 at BofA

Rocket Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan

2025-11-18T12:21:11.000Z - 6 months ago

Rocket Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan

Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Nov 6, 2025, 4:00 PM EST - 6 months ago

Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Oct 14, 2025, 7:00 AM EDT - 7 months ago

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 10, 2025, 4:00 PM EDT - 7 months ago

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder

Oct 3, 2025, 7:11 AM EDT - 7 months ago

Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder

Rocket Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 9:15 AM EDT - 8 months ago

Rocket Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Rocket Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 3:20 PM EDT - 8 months ago

Rocket Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.

Aug 20, 2025, 11:02 AM EDT - 9 months ago

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.

US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial

Aug 20, 2025, 7:09 AM EDT - 9 months ago

US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial

Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease

Aug 20, 2025, 7:00 AM EDT - 9 months ago

Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease

DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025

Aug 8, 2025, 2:16 PM EDT - 9 months ago

DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025

Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Aug 7, 2025, 4:00 PM EDT - 9 months ago

Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs

Jul 24, 2025, 7:00 AM EDT - 10 months ago

Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

Jul 17, 2025, 7:00 AM EDT - 10 months ago

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop

Jul 9, 2025, 5:16 PM EDT - 10 months ago

Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop

Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy

Jun 30, 2025, 7:00 AM EDT - 11 months ago

Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy

darntootin
darntootin May. 13 at 12:14 PM
$RCKT In the wider AAV gene therapy landscape, most approved or late-stage therapies act as "stabilizers" that slow down the decline of a degenerative disease. The Industry Benchmark: For example, Sarepta’s Elevidys (for Duchenne muscular dystrophy) or Novartis's Zolgensma (for Spinal Muscular Atrophy) are designed to halt or delay severe muscle wasting. They rarely restore lost function or drastically reduce structural damage that has already occurred. The RP-A501 Difference: Rocket's data goes beyond stabilization. Achieving a 24% reduction in left ventricular mass and completely reversing heart failure symptoms from NYHA Class II to Class I (asymptomatic) is viewed as an extraordinary breakthrough. It marks one of the few instances in gene therapy where a structural organ defect (cardiac hypertrophy) has been actively reversed humans
0 · Reply
Resilience1239
Resilience1239 May. 12 at 11:16 PM
$RCKT It took 3 years of holding and watching $AUPH go up and down, for one day to come home from work and you see its at $28. "Investing" is conviction and strength, strength to hold and strength to sell, vice versa. $RCKT will also get its run to the $30's. Just time and patience. 3220 shares strong and not selling, if you don't believe what's the point of the investment...
0 · Reply
xXCronoSXx
xXCronoSXx May. 12 at 1:51 PM
$RCKT pt? December? Next catalist?
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 12 at 1:26 PM
$RCKT RSI: 47.41, MACD: -0.0713 Vol: 0.16, MA20: 3.66, MA50: 4.03 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
darntootin
darntootin May. 11 at 9:53 PM
$RCKT I can wait not giving my shares to stuck shorts 🩳 for cheap
0 · Reply
Bellz22
Bellz22 May. 11 at 7:05 PM
$RCKT
0 · Reply
ctolliver1
ctolliver1 May. 11 at 3:10 PM
$RCKT why do they not close the ATM with the new funding available. Wouldn't that reassure investors?
4 · Reply
Shunbab
Shunbab May. 11 at 8:42 AM
$RCKT up over 4% premarket.... something afoot? 🤔
2 · Reply
BinaryLogic
BinaryLogic May. 9 at 11:02 AM
$MIST $RCKT $ABCL $OBIO $IMRX [Again] Investors are heavy in semi-conductors, AI/HPC and O&G related stocks presently which has created opportunities in-particular in biotechnology, small and large cap alike (IMO). That is not to suggest that major reversals here are imminent, but the setups are becoming increasingly opportunistic (IMO) intermediate term. UNCY COCH JSPR SCNX RANI TRAW NVAX MDT BSX
0 · Reply
drumma56
drumma56 May. 8 at 6:43 PM
$RCKT This is one F'd up ticker.
1 · Reply
Teillbou
Teillbou May. 8 at 4:09 PM
$RCKT I really don't understand. But the moment those 3 remaining patients are dosed safely, this will skyrock. It may happen next week maybe or next month who knows but soon !
0 · Reply
oaksapollo
oaksapollo May. 8 at 3:48 PM
$RCKT This is purely speculative, but how can a company like Chiesi or Alexion not be looking at acquiring Rocket right here? Rocket is flush with cash, with one approved product, and a robust pipeline. For someone looking to build a gene therapy business, it makes all the sense in the world, and it's so damn cheap with the EV <$100M.
1 · Reply
RickyIsRich
RickyIsRich May. 8 at 3:29 PM
$RCKT absolute nothing burger this company is horrible
0 · Reply
darntootin
darntootin May. 8 at 2:26 PM
$RCKT This stock will explode period shorts have a free shot with the borrowing rate so low but that will change and when it does BOOM 💥
0 · Reply
Orlandotrader
Orlandotrader May. 8 at 2:07 PM
$RCKT Pig
0 · Reply
cbowers8171
cbowers8171 May. 8 at 2:05 PM
$RCKT it's a trap!
0 · Reply
Bellz22
Bellz22 May. 8 at 2:02 PM
$RCKT motherfuckers
0 · Reply
jinzhou5042
jinzhou5042 May. 8 at 1:58 PM
$RCKT This stock really likes to tumble when good news come out, you guys should've known the lesson.
0 · Reply
StockRockCanada
StockRockCanada May. 8 at 1:39 PM
$RCKT As expected we are substantially higher after the ER.
1 · Reply
quickaspeter
quickaspeter May. 8 at 12:11 PM
$RCKT Q1 2026 ER highlights- - Pivotal Phase 2 trial of RP-A501 for Danon disease progressing with dosing reinitiated - First patient dosing in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in mid-2026 - KRESLADI™ granted FDA accelerated approval; Rare Pediatric Disease Priority Review Voucher monetized for $180 million - Pro forma cash, cash equivalents and investments of approximately $322.6 million, including balance as of March 31, 2026, and non-dilutive proceeds from the PRV sale; expected operational runway into the second quarter of 2028
0 · Reply
geegor
geegor May. 7 at 9:16 PM
$RCKT And a prod to Wall Street in the filing today: • Pivotal Phase 2 Trial of RP-A501 for Danon Disease Progressing With Dosing Reinitiated • First Patient Dosing in Phase 1 Study of RP-A701 for BAG3-related Dilated Cardiomyopathy Anticipated in Mid-2026
3 · Reply
geegor
geegor May. 7 at 8:38 PM
$RCKT even expenses have been brought under greater control: Research and development expenses were $31.5 million for the three months ended March 31, 2026, compared to $35.9 million for the three months ended March 31, 2025. General and administrative expenses were $17.1 million for the three months ended March 31, 2026, compared to $28.4 million for the three months ended March 31, 2025.
0 · Reply